Avacta

• 25/04/12

  Interim Results

• 02/04/12

  Avacta Signs Exclusive Supply Deal with IDEXX

• 15/03/12

  Notice of Interim Results

• 24/01/12

  Result of AGM

• 19/01/12

  Holding(s) in Company

• 12/01/12

  Holding(s) in Company

• 10/01/12

  Completes ?5.13m placing and Aptuscan acquisition

• 09/01/12

  Results of General Meeting

• 08/12/11

  Notice of AGM and Report and Accounts

• 25/11/11

  Additional Listing & Total Voting Rights

• 

  07/03/11

  Avacta Group: Optim sales growth and Pall Corp tie-up puts group in ‘higher league’

  On Friday the AIM-listed bio-technology group told investors that it has seen growing sales momentum in recent months, particularly for its Optim biophysical analysis product. Indeed it has been an interesting stock to watch in the past three months. The shares have almost tripled in value, it has signed up a blue-chip partner and its revenues are growing. XCap Securities Tim Freeborn reckons the stock could be worth 2.5 pence a share as the new deal takes the firm into a ‘higher league”.

   

• 09/08/11

  Avacta Group hails Optim sales as announces trading update

• 04/03/11

  Avacta says it made good commercial progress in tough economic climate

• 23/04/09

  Avacta on the brink of becoming revenue-generating

• 09/02/09

  Avacta Group acquires YorkTest Vet Services for £0.825 million

Connect with Facebook to view or add comments for this company